论文部分内容阅读
Objective: A recent phase 3 study (PARAMOUNT) demonstrated that continuation maintenance therapy of pemetrexed is a new treatment paradigm for advanced nonsquamous NSCLC.The majority of patients enrolled in PARAMOUNT were Caucasian.The objective of this review is to evaluate the efficacy and safety of pemetrexed continuation maintenance therapy in East Asian patients.